Novartis: 'real world' data shows psoriasis drug efficacy

(CercleFinance.com) - Real-world data has confirmed the efficacy of Novartis' Cosentyx in daily life for patients suffering from psoriasis, the Swiss drugmaker said on Thursday.


New data from several real-world sources in moderate-to-severe plaque psoriasis confirmed that Cosentyx led to a pronounced improvement in the quality of patients' lives, it said.

More specifically, 59% of patients had no or little impact of their skin disease on their quality of life after 24 weeks of treatment, Novartis said.

Additional real-world data showed that 87% of bio-naive psoriasis patients remain on Cosentyx after 12 months of treatment, further supporting the use of Cosentyx in real-world settings.

All this data was first presented at the European Academy of Dermatology and Venereology (EADV) Congress in Paris.

Copyright (c) 2018 CercleFinance.com. All rights reserved.